BLAINJECTIONSOLUTIONPriority Review
Approved
Oct 2020
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
2/8 — Basic
Priority Review
Drug data last refreshed 16h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
INMAZEB is a monoclonal antibody (mAb) combination therapy comprised of atoltivimab, maftivimab, and odesivimab-ebgn, administered as an intravenous injection. It is indicated for the treatment of Ebola virus infection (Zaire ebolavirus) in adult and pediatric patients. The triple antibody cocktail targets multiple epitopes on the Ebola virus glycoprotein to neutralize viral activity.
Peak
Peak lifecycle stage with moderate competitive pressure (30) indicates stable team size and ongoing commercial optimization efforts for this specialized indication.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Impact of Delay Between Administration of Inmazeb Administration and Vaccination by Ervebo on Vaccine Immune Response on Healthy Volunteers
Started Jan 2027
132 enrolled
Ebola Virus Disease
Career Relevance
Working on INMAZEB offers 540 linked career opportunities across R&D, regulatory, quality, and medical affairs, with leadership roles heavily represented. This is a specialized, mission-critical product that attracts scientists and directors focused on rare but high-impact infectious disease, offering unique visibility and career differentiation within Regeneron.
Manager
Worked on INMAZEB at Regeneron? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.